Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 lumicitabine study in hospitalized infants and young children with RSV infection
2017-001862-56Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing Lumicitabine regimen(s) with Placebo (2 arms). Primary endpoint: RSV RNA log10 viral load AUC over 7 days. Started Jul 2017; status: terminated.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2017-001862-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001862-56.